Clinical Trials in Australia and New Zealand

Abbott Australasia conducts a number of Clinical Trials in a range of different disease areas. These trials provide access to new or existing drugs for many patients. Our Clinical Trials cover all phases of clinical research from Phase I through to Phase IV including post-marketing observation studies. A number of Investigator Initiated Studies are also managed through Abbott Australasia.

Abbott Australasia is currently enrolling patients in Clinical Trials in the following disease areas:

• Cancer – Solid Tumours
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Uveitis

If you are an Investigator and interested in conducting a clinical trial, please contact clinicaltrials_ANZ@abbott.com or call +61 (0)2 9384 9700 and ask for the Clinical Department.

If you are a patient interested in participating in a Clinical Trial that is currently recruiting patients, please see the individual Clinical Trial information below.

Please note that Abbott Australasia have potential upcoming Clinical Trials that have not yet been opened to recruitment. This website is updated regularly with newly recruiting Clinical Trials. Please visit our website again for future updates.

Patient Information for Participating in Clinical Trials

Each Clinical Trial listed below has a brief description and a link to a page on the www.clinicaltrials.gov website, which provides a much more detailed description of the Clinical Trial. If you would like to participate in a Clinical Trial that is currently enrolling or would like further information, please use the links provided below to access the relevant contact numbers for the hospitals and medical centres involved. This can be found by clicking on the Study Location link on each Clinical Trial website. If you are unable to find the relevant hospital or medical centre, please contact clinicaltrials_ANZ@abbott.com or call +61 (0)2 9384 9700 and ask for the Clinical Department for further information.

The following studies are currently recruiting:

Cancer – Solid Tumours

M11-849: Currently Recruiting

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects with Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR).

This Clinical Trial is currently or will be recruiting patients in the Brisbane and Melbourne areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01472003?term=m11-849&rank=1

M12-326: Currently Recruiting

An Extension Study of ABT-806 for Subjects with Advanced Solid Tumors.

This Clinical Trial is currently or will be recruiting patients in the Brisbane and Melbourne areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT01406119?term=m12-326&rank=1

Juvenile Idiopathic Arthritis

P10-262: Currently Recruiting

A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - STRIVE.

This Clinical Trial is currently or will be recruiting patients in the Adelaide, Newcastle, Perth, and Sydney areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00783510?term=P10-262&rank=1

Rheumatoid Arthritis

P12-072: Currently Recruiting

A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis.

This Clinical Trial is currently or will be recruiting patients in the Coffs Harbour, Geelong, Melbourne, Newcastle, Perth, and Sydney areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01383421?term=p12-072&rank=1

Uveitis

M10-880: Currently Recruiting

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis.

This Clinical Trial is currently or will be recruiting patients in the Melbourne and Perth areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT01124838?term=M10-880&rank=1

M10-877: Currently Recruiting

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis.

This Clinical Trial is currently or will be recruiting patients in the Melbourne and Perth areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT01138657?term=M10-877&rank=1

M11-327: Currently Recruiting

A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis.

This Clinical Trial is currently or will be recruiting patients in the Melbourne and Perth areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01148225?term=m11-327&rank=1

The following studies are active, but closed to recruitment:

Axial Spondyloarthritis

M10-791: Active, but Closed to Recruitment

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis.

This Clinical Trial is active, but has closed to recruitment in the Brisbane, Maroochydore, and Sydney areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00939003?term=m10-791&rank=1

Colorectal Cancer

M10-300: Active, but Closed to Recruitment

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination with mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination with mFOLFOX6 as Second-line Treatment of Subjects with Advanced Colorectal Cancer.

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Brisbane, Gold Coast, Melbourne, Perth and Wellington areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT00707889?term=M10-300&rank=1

Hepatocellular (Liver) Cancer

M10-963: Active, but Closed to Recruitment

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC).

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Auckland, Cairns, Gold Coast, and Sydney areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT01009593?term=M10-963&rank=1

Leukemia

M10-166: Active, but Closed to Recruitment

A Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Rituximab in Subjects with CD20-positive Lymphoid Malignancies.

This Clinical Trial is active, but has closed to recruitment in the Melbourne area. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00788684?term=m10-166&rank=1

M06-873: Active, but Closed to Recruitment

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.

This Clinical Trial is active, but has closed to recruitment in the Melbourne area. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00481091?term=m06-873&rank=1

Lung Cancer

M10-301: Active, but Closed to Recruitment

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment.

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Cairns, Christchurch, Melbourne, Northern NSW, and Perth areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT00716534?term=M10-301&rank=1

Melanoma

M10-440: Active, but Closed to Recruitment

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma.

This Clinical Trial is active, but has closed to recruitment in the Auckland, Brisbane, Melbourne, Nambour, Newcastle, Perth, Sydney, and Wellington areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00804908?term=m10-440&rank=1

Ovarian Cancer

M10-757: Active, but Closed to Recruitment

A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer.

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Auckland, Melbourne, Perth, and Sydney areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01113957?term=m10-757&rank=1

Peripheral Spondyloarthritis

M10-883: Active, but Closed to Recruitment

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis.

This Clinical Trial is active, but has closed to recruitment in the Hobart, Maroochydore, Melbourne, and Perth areas. For further information, please visit: http://clinicaltrials.gov/ct2/show/NCT01064856?term=M10-883&rank=1

Rheumatoid Arthritis

DE-013: Active, but Closed to Recruitment

A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFa Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatiod Arthritis (PREMIER).

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Brisbane, Maroochydore, Melbourne, Newcastle, Perth, and Sydney areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00195663?term=de-013&rank=1

Ulcerative Colitis

M10-223: Active, but Closed to Recruitment

A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis.

This Clinical Trial is active, but has closed to recruitment in the Adelaide, Auckland, Brisbane, Canberra, Christchurch, Fremantle, and Melbourne areas. For further information, please visit: http://www.clinicaltrials.gov/ct2/show/NCT00573794?term=m10-223&rank=1